LungLifeAI Logo

News & Updates

Our Purpose:
To be a driving force in the early detection of lung cancer.

August 14, 2023

Director share purchases

LungLife AI, Inc. (the “Company” or “LungLife”)  Director share purchases LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces that it has received notification of the following transactions in the Company’s common shares of US $0.0001 each (“Common Shares”) undertaken by directors. On 14 August 2023, […]
• Read More
August 8, 2023

Half-year Report

LungLife AI, Inc. (the “Company” or “LungLife”)  Half-year Report  LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer announces its unaudited half-year report for the six months ended 30 June 2023. Operational Highlights: Completed enrolment of the Company’s 425-participant pivotal clinical validation study in May, in line […]
• Read More
August 3, 2023

Notice of Results

3 August 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Notice of Results Investor Presentation LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, will announce its unaudited half-year report for the six months ended 30 June 2023 on Tuesday 8 August 2023. Investor presentation Paul Pagano, […]
• Read More
June 6, 2023

LungLB® study demonstrating high performance published in peer-reviewed journal

6 June 2023 LungLife AI, Inc. (the “Company” or “LungLife”) LungLB® study demonstrating high performance published in peer-reviewed journal LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the publication of successful performance results for the Company’s blood-based LungLB® test from a multi-site prospective study in patients with indeterminate pulmonary […]
• Read More
May 23, 2023

Enrolment completed for pivotal validation study of LungLB®

23 May 2023 LungLife AI, Inc. (the “Company” or “LungLife”)  Enrolment completed for pivotal validation study of LungLB® Company to work with clinical sites to ensure data quality ahead of analysis and readout  LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the completion of enrolment for its prospective, pivotal […]
• Read More
May 15, 2023

Block Listing Six Monthly Return

15 May 2023 LungLife AI, Inc. ("LungLife" or the "Company") Block Listing Six Monthly Return LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies: Name of applicant: […]
• Read More
May 4, 2023

Result of Annual General Meeting

4 May 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Result of Annual General Meeting LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at its Annual General Meeting, held at earlier today, all 10 resolutions put to members were passed on a poll. The number of votes lodged […]
• Read More
May 2, 2023

Confirmation of AGM

2 May 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Confirmation of AGM LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, confirms that its Annual General Meeting ("AGM") will be held at 3:00 P.M. (BST) on Thursday 4 May 2023, at Investec Bank plc, 30 Gresham Street, London, EC2V 7QP. […]
• Read More
April 6, 2023

Publication of Annual Report and Accounts & Notice of AGM

06 April 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Publication of Annual Report and Accounts & Notice of AGM LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Annual Report and Accounts, Notice of Annual General Meeting ("AGM"), Form of Direction and associated Form of Proxy are now […]
• Read More
March 14, 2023

Appointment of Joint Broker

14 March 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Appointment of Joint Broker LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the appointment of Goodbody as the Company's Joint Broker with immediate effect. Investec Bank plc remains Nominated Adviser and Joint Broker to the Company.  Click HERE for […]
• Read More

Investor inquiries

LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
crosschevron-down